Effect of dexmedetomidine on cognition, immune inflammatory reaction and oxidative stress in lung cancer patients with VATS
10.3760/cma.j.issn.1008-6706.2019.19.015
- VernacularTitle: 右美托咪定对肺癌患者胸腔镜术后认知、免疫炎性反应及氧化应激的影响
- Author:
Jing LIU
1
;
Yuhong TIAN
1
;
Congcong MIAO
2
Author Information
1. Department of Anesthesiology, the Second Hospital of Qinhuangdao, Qinhuangdao, Hebei 066600, China
2. Department of Clinical Laboratory, The Second Hospital of Qinhuangdao, Qinhuangdao, Hebei 066600, China
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Thoracoscopy;
Anaesthesia;
Cognition;
Autoimmunity;
Inflammation;
Oxidative stress;
Dexmedetomidine
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(19):2371-2376
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of dexmedetomidine on cognition (MMSE score), immune inflammatory reaction and oxidative stress in lung cancer patients with VATS.
Methods:From January 2016 to December 2017, 89 lung cancer patients underwent VATS in the Second Hospital of Qinhuangdao were randomly divided into the control group (n=46) and the dexmedetomidine group (n=43) according to the digital table.The MMES, CD4 and CD8 lymphocytes, inflammatory factors and oxidative stress factors were compared between the two groups before operation (T0) and at 3 hours (T1), 12 hours (T2), 24 hours (T3) after operation.
Results:There were no statistically significant differences in MMSE, CD4 and CD8 lymphocytes, inflammatory factors and oxidative stress factors between the two groups (P>0.05). At the time points of T1, T2 and T3, MMSE scores decreased in both two groups, but the MMSE score in the dexmedetomidine group was higher than those in the control group [(27.67±1.97)points vs.(25.61±1.81)points, (26.47±1.92)points vs.(24.70±2.26)points, (26.16±1.90)pouints vs.(23.41±2.33)points, t=-2.122, -2.553, -2.528, P=0.037, 0.012, 0.013]. The CD8 lymphocyte, inflammatory factors and oxidative stress factors increased after operation in both two groups, and dexmedetomidine could inhibit the increase of immune inflammatory factors and oxidative response factors(IL-6: t=3.038, 2.489, 3.291, P=0.003, 0.015, 0.001; hsCRP: t=2.147, 2.164, 2.752, P=0.035, 0.033, 0.007; TNF-α: t=2.119, 2.323, 2.485, P=0.037, 0.023, 0.015; MDA: t=2.499, 2.116, 2.094, P=0.014, 0.037, 0.039; MPO: t=2.190, 2.166, 2.849, P=0.031, 0.033, 0.005; SOD: t=-2.551, -2.598, -3.141, P=0.012, 0.011, 0.002). The incidence rate of adverse reactions in dexmedetomidine group was lower than that in control group(6/43 vs.18/46, P=0.011).
Conclusion:Dexmedetomidine can improve cognition, reduce immune inflammatory reaction and oxidative stress, and alleviate adverse effects in lung cancer patients with VATS.
